BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• Business

  Nuovo Biologics, LLC. Announces Academic-Biotech Collaboration With Auburn University’s Research Initiative In Cancer

  June 1, 2015

   · 

  1 min read
• Biotech Beach

  Epic Sciences Expands Silicon Valley Bank Credit Facility

  June 1, 2015

   · 

  3 min read
• Drug Development

  ASCO15: Juno Therapeutics’s Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses In Patients With B-Cell Cancers

  June 1, 2015

   · 

  4 min read
• Drug Development

  Exelixis Announces Positive Results From Phase 2 Investigator-Sponsored Trial Of Cabozantinib In RET-Rearranged Non-Small Cell Lung Cancers

  June 1, 2015

   · 

  9 min read
• Drug Development

  Roche’s Perjeta Regimen Helped People With HER2-Positive Early Breast Cancer Live Longer Without Their Disease Returning Or Getting Worse Compared To Herceptin And Chemotherapy

  June 1, 2015

   · 

  8 min read
• Drug Development

  Pharming Group Announces Interim Results From The Ongoing Phase II Pediatric Clinical Trial Of Ruconest

  June 1, 2015

   · 

  7 min read
• Business

  Motif Partners With Leading Global CRO For Phase III Clinical Trials With Iclaprim

  June 1, 2015

   · 

  2 min read
• Drug Development

  ASCO15: Momenta To Present New Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer

  June 1, 2015

   · 

  6 min read
• Drug Development

  BioLineRx Ltd. Announces Peer-Reviewed Publication Of Phase 1/2 Trial Results For Novel Treatment For Non-Surgical Removal Of Skin Lesions

  June 1, 2015

   · 

  5 min read
• Drug Development

  ASCO15: TG Therapeutics, Inc. Announces The Triple Combination Of TG-1101, TGR-1202 And Ibrutinib Is Safe And Highly Active In Patients With Advanced B-Cell Malignancies

  June 1, 2015

   · 

  9 min read